Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
List view / Grid view
US National Cancer Institute (NCI)
Filter the results
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.